Claire, 3 years, has Dravet Syndrome. Her neurologist has recommended she undertake a trial with CBD with the aim of achieving better seizure control. A 100 mg/ml CBD oral liquid product is now listed on the Pharmaceutical Benefits Scheme (PBS) for Dravet Syndrome when used in combination with at least two other anti-epileptic medicines. She is already taking clobazam and sodium valproate.
After successful completion of this CPD activity, pharmacists should be able to:
Competency standards (2016) addressed: 1.1, 1.4, 1.5, 2.2, 3.1, 3.5
Already read the CPD in the journal? Scroll to the bottom to SUBMIT ANSWERS.
The medicinal cannabis article published previously by Australian Pharmacist, focused on the role of the pharmacist in the provision of medicinal cannabinoids. This article will provide a more detailed look at the evidence for specific indications and considerations for the use of medicinal cannabis in epilepsy, pain, multiple sclerosis, nausea and vomiting, and palliation.
In Australia, there are currently two Therapeutic Goods Administration (TGA)-approved medicinal cannabinoid products, with indications for symptom improvement of multiple sclerosis and two rare childhood epilepsies.
THIS IS A CPD ARTICLE. YOU NEED TO BE A PSA MEMBER AND LOGGED IN TO READ MORE.